Evidence map›Paper›PMID 35785236›Full record

ArticleHeliyon2022

Inhibitory effects of Triphala on CYP isoforms

Jannarin Nontakham, Pongpun Siripong, Hitoshi Sato, Savita Chewchinda, Kuntarat Arunrungvichian, Jantana Yahuafai, Arman Syah Goli, Vilasinee Hirunpanich Sato

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jannarin NontakhamDepartment of Pharmacology, Mahidol University, Bangkok, Thailand.
Pongpun SiripongDivision of Research and Academic Support, National Cancer Institute, Bangkok, Thailand.
Hitoshi SatoDepartment of Pharmacology, Therapeutics and Toxicology, School of Pharmacy, Showa University, Tokyo, Japan.
Savita ChewchindaDepartment of Food Chemistry, Mahidol University, Bangkok, Thailand.
Kuntarat ArunrungvichianDepartment of Pharmaceutical Chemistry, Mahidol University, Bangkok, Thailand.
Jantana YahuafaiDivision of Research and Academic Support, National Cancer Institute, Bangkok, Thailand.
Arman Syah GoliDepartment of Pharmacology, Mahidol University, Bangkok, Thailand.
Vilasinee Hirunpanich SatoDepartment of Pharmacology, Mahidol University, Bangkok, Thailand.
Mahidol University · THNational Cancer Institute of Thailand · THShowa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Direct evidence of Triphala-drug interactions has not been provided to date. Objective: This study was aimed to determine the effects of Triphala on cytochrome P450 (CYP) isoforms and P-glycoprotein (P-gp) Materials and methods: Effects of Triphala on the activities of CYP isoforms and P-gp were examined using human liver microsomes (HLMs) and Caco-2 cells, respectively. Pharmacokinetic interactions between Triphala and CYP-probes (i.e., phenacetin and midazolam) were further examined in rats. Results: Triphala extract inhibited the activities of CYP isoforms in the order of CYP1A2>3A4>2C9>2D6 with the IC Discussion and conclusions: Increases observed in the bioavailabilities of phenacetin and midazolam after oral co-administration of Triphala in rats provided a direct line of evidence to show Triphala-drug interactions

Indexed as

Cytochrome P450MidazolamP-glycoproteinPharmacokinetic interactionPhenacetinTriphala extract

Identifiers

PMID35785236
PMCPMC9243172
OpenAlexW4283160938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.